| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/30/2000 | US6068838 Purified multimerase having proteolytic activity, converts von willebrand factor having a singlet structure to von willebrand factor having satellite structure and is active in presence of serine protease and calpin protease inhibitor |
| 05/30/2000 | US6068837 Mesothelial cell gene therapy |
| 05/30/2000 | US6068833 Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol |
| 05/30/2000 | US6068832 Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| 05/30/2000 | US6068630 Spine distraction implant |
| 05/30/2000 | CA2206104C Adamantyl substituted oxindoles as pharmaceuticals agents |
| 05/30/2000 | CA2205600C Freeze-dried ondansetron compositions |
| 05/30/2000 | CA2182707C 3'-substituted nucleoside derivative |
| 05/30/2000 | CA2171844C Sustained release formulations for 24 hour release of metoprolol |
| 05/30/2000 | CA2159326C Method for treating amyloidosis |
| 05/30/2000 | CA2144407C Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 05/30/2000 | CA2143497C Self-tan cosmetic compositions containing dihydroxyacetone; process for preparing the same and their use |
| 05/30/2000 | CA2120045C Use of hyaluronic acid and forms to prevent arterial restenosis |
| 05/30/2000 | CA2086094C Vaccine compositions containing liposomes |
| 05/30/2000 | CA2083333C High dosage topical forms of collagenase |
| 05/30/2000 | CA2050067C Controlled drug release composition |
| 05/30/2000 | CA2024880C 10-(1-hydroxyethyl)-11-oxo-1-azatricyclo(7.2.0.0.3,8)undec-2-ene-2-2-ca rboxylic acid derivatives |
| 05/30/2000 | CA2014889C Intra-rectal pharmaceutical foam compositions |
| 05/30/2000 | CA2014645C Pharmaceutical compounds |
| 05/30/2000 | CA2012226C Olefinic 1h-imidazo [4,5-c]quinolin-4-amines |
| 05/30/2000 | CA2004747C Substituted phenylpyrimidines useful in the treatment of cns disorders |
| 05/30/2000 | CA2002472C Liquid oral formulation |
| 05/30/2000 | CA1341011C Benzo-fused cycloalkane and oxa- and thia-, cycloalkane trans-1,2-diamine derivatives |
| 05/26/2000 | CA2252967A1 Protein fragments for use in protein targeting |
| 05/26/2000 | CA2252966A1 Viral therapeutics |
| 05/25/2000 | WO2000029623A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | WO2000029601A1 A method for depopulating of vertebrate testis and for generation of transgenic species |
| 05/25/2000 | WO2000029598A1 Novel recombinant adenovirus |
| 05/25/2000 | WO2000029564A2 Human glycine transporter type 2 |
| 05/25/2000 | WO2000029556A2 Identification of glycosphingolipids that promote hiv-1 entry into cells |
| 05/25/2000 | WO2000029481A1 Anionic-cationic polyion complexes comprising zwitterionic monomer component |
| 05/25/2000 | WO2000029438A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 05/25/2000 | WO2000029435A1 12 human secreted proteins |
| 05/25/2000 | WO2000029412A1 PENTAAZA-CYCLOPENTA[A]NAPHTHALENE DERIVATIVES AS LIGANDS FOR GABAA α5 RECEPTORS |
| 05/25/2000 | WO2000029408A1 Morpholino-ethoxybenzofuran protease inhibitors |
| 05/25/2000 | WO2000029403A1 Novel pyrimidine derivatives and processes for the preparation thereof |
| 05/25/2000 | WO2000029402A1 Method of preparing delta-9-tetrahydrocannabinol esters |
| 05/25/2000 | WO2000029401A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | WO2000029397A1 New piperazine and piperidine compounds |
| 05/25/2000 | WO2000029389A1 6-(3-carboxymethylphenyl)-aminouracyl having a biological activity |
| 05/25/2000 | WO2000029384A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 05/25/2000 | WO2000029383A1 Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide |
| 05/25/2000 | WO2000029382A1 Certain substituted caprolactams, pharmaceutical compositions containing them and their use in treating tumors |
| 05/25/2000 | WO2000029381A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | WO2000029379A1 1-aminoethylquinoline derivatives for treating urinary incontinence |
| 05/25/2000 | WO2000029377A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 05/25/2000 | WO2000029371A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | WO2000029103A1 Method and apparatus for liposome production |
| 05/25/2000 | WO2000029043A1 Bioactive prostheses with immunosuppressive, antistenotic and antithrombotic properties |
| 05/25/2000 | WO2000029029A1 Compositions and methods for producing vascular occlusion |
| 05/25/2000 | WO2000029027A1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 05/25/2000 | WO2000029025A1 Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 05/25/2000 | WO2000029023A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| 05/25/2000 | WO2000029021A1 Percutaneously administrable preparations containing cerebral function activators |
| 05/25/2000 | WO2000029015A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 05/25/2000 | WO2000029008A2 Hiv-specific t-cell induction |
| 05/25/2000 | WO2000029006A1 Composition for suppressing appetite and for achieving an alert, yet calm state |
| 05/25/2000 | WO2000029005A1 Method for producing an agent for treating non-cancerous pathologies of the organism |
| 05/25/2000 | WO2000028999A2 Methods of treating tardive dyskinesia and other movement disorders |
| 05/25/2000 | WO2000028996A1 Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides |
| 05/25/2000 | WO2000028995A1 Graduated progestin contraceptive |
| 05/25/2000 | WO2000028994A1 Copolymer compositions for treating viral infections |
| 05/25/2000 | WO2000028993A1 Serotonin ligands as pro-erectile compounds |
| 05/25/2000 | WO2000028992A1 Riluzole and alpha-tocopherol combination |
| 05/25/2000 | WO2000028991A1 Remedies for polycystic ovary syndrome |
| 05/25/2000 | WO2000028990A1 Pharmaceutical composition for modified release insulin sensitiser |
| 05/25/2000 | WO2000028989A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | WO2000028988A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | WO2000028987A1 Methods of treating thrombocytopenia |
| 05/25/2000 | WO2000028986A1 Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis |
| 05/25/2000 | WO2000028985A1 Method of treating seizure disorders |
| 05/25/2000 | WO2000028984A1 Remedies for digestive tract functional disorder |
| 05/25/2000 | WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 05/25/2000 | WO2000028982A2 Increasing bone strength with selected bisphosphonates |
| 05/25/2000 | WO2000028981A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | WO2000028980A2 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
| 05/25/2000 | WO2000028979A1 Dry powder for inhalation |
| 05/25/2000 | WO2000028977A1 Antioxidant gel for gingival conditions |
| 05/25/2000 | WO2000028975A2 Improved chemical process and pharmaceutical formulation |
| 05/25/2000 | WO2000028974A1 Local delivery of drugs to the colon for local treatment of colonic diseases |
| 05/25/2000 | WO2000028973A1 Process for preparing oral calcium compositions |
| 05/25/2000 | WO2000028971A1 Nano-emulsion of 5-aminolevulinic acid |
| 05/25/2000 | WO2000028970A1 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 05/25/2000 | WO2000028968A1 Drug delivery device, especially for the delivery of progestins and estrogens |
| 05/25/2000 | WO2000028967A1 Drug delivery device, especially for the delivery of androgens |
| 05/25/2000 | WO2000028958A1 Topical compositions including deodorant compositions |
| 05/25/2000 | WO2000028954A1 Method for inhibiting dental resorptive lesions |
| 05/25/2000 | WO2000028950A1 Novel fatty ammonium quaternary compositions |
| 05/25/2000 | WO2000028947A2 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | WO2000028945A2 Anticonvulsant derivatives useful in treating post traumatic stress disorder |
| 05/25/2000 | WO2000028944A2 Use of succinic acid or salts thereof and method of treating insulin resistance |
| 05/25/2000 | WO2000028920A1 Therapeutic use of polymers |
| 05/25/2000 | WO2000028838A1 Calcium fortified juice-based nutritional supplement |
| 05/25/2000 | WO2000028835A1 A method for supplying bioavailable methionine to a cow |
| 05/25/2000 | WO2000028821A1 Therapeutic anti-fungal nail preparation |
| 05/25/2000 | WO2000028817A1 Teat disinfectant |
| 05/25/2000 | WO2000021528A8 Use of ophthalmic composition comprising vitamin a and vitamin e |
| 05/25/2000 | WO2000018385A3 Use of acylcarnitines as antitumour agents |
| 05/25/2000 | WO2000018361A3 Method of treating hair loss using sulfonamides |
| 05/25/2000 | WO2000018254A3 Method of protecting heat- or oxygen-labile compounds to preserve activity and bioavailability |